CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Evaluation of Exposures to Healthcare Personnel from Cisplatin during a Mock Interperitoneal Operation
-
2010/03/01
-
Source: Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, HETA 2009-0121-3106, 2010 Mar; :1-21
[PDF-4.00 MB]
Details:
-
Personal Author:
-
Corporate Authors:
-
Description:On March 24, 2009, NIOSH received a management request for an HHE at the UMC, in Las Vegas, Nevada. The HHE request was submitted because a new medical procedure was being proposed, and some hospital staff were concerned about potential exposures to cisplatin. On May 11-12, 2009, we visited UMC to evaluate potential exposures to cisplatin during a mock demonstration of the new interperitoneal procedure. We collected GA and PBZ air samples and wipe samples for cisplatin. We evaluated the effectiveness of the chemotherapy-approved gloves worn by the employees by asking employees to wear cotton gloves beneath their chemotherapy-approved gloves. These cotton glove samples were then analyzed for cisplatin. No cisplatin was detected in any GA air samples (MDC = 0.016 microg/m3), personal breathing zone air samples (MDC = 0.058 microg/m3), or cotton glove samples (LOD = 0.009 microg/sample). Cisplatin was detected above the LOQ of 0.031 microg/sample on one of the 15 wipe samples taken. This surface wipe sample was taken on the operating room floor near the surgical technician. No cisplatin was detected in surface wipe samples taken in the same area both prior to the interperitoneal procedure and after the room was sanitized (LOD = 0.007 microg/sample). This suggests that the UMC environmental services staff effectively removed any cisplatin contamination following the interperitoneal procedure. We recommend that employees continue to double-glove by wearing two pairs of chemotherapy-protective gloves. We also recommend that management stress to employees the importance of minimizing splashes and spills. Cisplatin solution splashes or spills should be cleaned up promptly with proper disposal in chemotherapy receptacles.
-
Subjects:
-
Keywords:
-
Source:
-
Series:
-
Subseries:
-
DOI:
-
Publisher:
-
Document Type:
-
Genre:
-
Place as Subject:
-
CIO:
-
Division:
-
Topic:
-
Location:
-
Pages in Document:28 pdf pages
-
Contributor:Evans, Stefanie M.;Galloway, Ellen;Smith, Robin;
-
NIOSHTIC Number:20036599
-
NTIS Accession Number:PB2010-107515
-
Citation:NIOSH [2010]. Health hazard evaluation report: evaluation of exposures to;healthcare personnel from cisplatin during a mock interperitoneal operation,;Las Vegas, NV. By Couch J and Burr G. Cincinnati, OH: U.S. Department of;Health and Human Services, Centers for Disease Control and Prevention,;National Institute for Occupational Safety and Health, NIOSH HETA No. 2009-;0121-3106,;
-
CAS Registry Number:
-
Federal Fiscal Year:2010
-
NORA Priority Area:
-
Peer Reviewed:False
-
NAICS and SIC Codes:
-
Resource Number:HETA-2009-0121-3106
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
